Topoisomerase-1 Inhibitor LMP744

Phase 1

MMayo Clinic

Topoisomerase-1 Inhibitor LMP744 is one of 46 therapeutic programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

GliomaRecruiting

GliomaPhase 1

Recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Keytruda

Merck & Co.

Phase 2

5 7

Verzenio

Eli Lilly

Phase 2

3 8

Lynparza

AstraZeneca

Phase 2

3 9

Dostarlimab

Incyte

Phase 2

2 10

Oncovin

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Glioma

NCT07025226

Clinical

Trials by Indication[1]

Glioma1 trial

MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

Recruiting·MMayo Clinic·Phase 1·NCT07025226·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topoisomerase-1 Inhibitor LMP744. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Topoisomerase-1 Inhibitor LMP744. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMayo Clinic

Topoisomerase-1 Inhibitor LMP744

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Glioma1 trial

References

Drug Info

Quick Facts

Related News